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Cross-reactive antibodies elicited by dengue virus (DENV) 
infection might affect Zika virus infection and confound se-
rologic tests. Recent data demonstrate neutralization of Zika 
virus by monoclonal antibodies or human serum collected 
early after DENV infection. Whether this finding is true in late 
DENV convalescence (>6 months after infection) is unknown. 
We studied late convalescent serum samples from persons 
with prior DENV or Zika virus exposure. Despite extensive 
cross-reactivity in IgG binding, Zika virus neutralization was 
not observed among primary DENV infections. We observed 
low-frequency (23%) Zika virus cross-neutralization in repeat 
DENV infections. DENV-immune persons who had Zika vi-
rus as a secondary infection had distinct populations of anti-
bodies that neutralized DENVs and Zika virus, as shown by 
DENV-reactive antibody depletion experiments. These data 
suggest that most DENV infections do not induce durable, 
high-level Zika virus cross-neutralizing antibodies. Zika vi-
rus–specific antibody populations develop after Zika virus 
infection irrespective of prior DENV immunity.
Zika virus is a member of the flavivirus family of arthro-podborne viruses, which includes West Nile virus, yel-
low fever virus, tick-borne encephalitis virus, and dengue 
virus (DENV) (1). The recent emergence of Zika virus in 
the Western Hemisphere caused widespread international 
concern. Although Zika virus infection is most commonly 
asymptomatic or causes only a mild, self-limited illness, 
recent epidemics have revealed new manifestations of Zika 
virus disease, including Guillain-Barré syndrome (2,3) and 
sexual transmission (4). Most alarmingly, and distinct from 
other flaviviruses, Zika virus infection during pregnancy 
can result in a spectrum of developmental abnormalities 
(congenital Zika syndrome) (5), which can include ocular 
damage, microcephaly, and fetal death (6). These manifes-
tations raise public health challenges unique from those of 
other vectorborne diseases, particularly preventing sexual 
transmission and protecting pregnant women.
Given shared ecology and mosquito vectors, Zika virus 
is emerging in areas with endemic DENV transmission. In 
many areas of Latin America, most persons has been exposed 
to >1 natural DENV infections (7); in some regions, DENV 
vaccination has been implemented or is in clinical trials (8). 
Because there is known serologic cross-reactivity between 
Zika virus and DENV (9), determining how DENV immunity 
affects subsequent Zika virus infection is important.
The ability of flavivirus infection to induce antibod-
ies that are virus-specific and that cross-react with different 
flaviviruses is well known (10–13), and flaviviruses have 
been grouped as serocomplexes on the basis of degree of 
antigenic overlap (11). Zika virus has not been studied ex-
tensively in this context; although it shares 54%–58% of its 
nucleotide sequence with the 4 serotypes of DENV in the 
envelope protein coding sequence (14), the extent to which 
Zika virus will group antigenically with the DENV sero-
complex is unclear. Several groups recently reported that 
antibodies isolated from persons with prior DENV infec-
tions cross-neutralize Zika virus and cross-protect in ani-
mal models of Zika virus infection (15–19). These results 
raise the possibility of DENV infections or vaccines cross-
protecting against Zika virus. Moreover, researchers have 
been concerned that the plaque/focus reduction neutraliza-
tion test, the standard serologic assay for distinguishing 
different flavivirus serocomplexes, will be unable to differ-
entiate Zika virus from DENV. During 2016 in North Caro-
lina, USA, we studied whether persons exposed to DENV 
maintain cross-neutralizing antibodies to Zika virus.
Methods
Human Subjects and Immune Serum
Serum was collected from North Carolina residents who 
had probable or confirmed DENV or Zika virus infection 
on the basis of self-reported symptoms and travel to ar-
eas in which these viruses are endemic. Serum samples 
from this study were assigned consecutive and arbitrary 
identification numbers such as DT165. A subset of DENV 
immune serum was obtained from a reference panel dis-
tributed by the Pediatric Dengue Vaccine Initiative. Sam-
ples were tested by virus-capture ELISA, and DENV- or 
Zika virus–reactive serum was further characterized by 
neutralization assays on Vero cells. All donations were 
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collected in compliance with the Institutional Review 
Board of the University of North Carolina at Chapel Hill 
(protocol 08–0895).
Serum that had neutralizing antibodies to 1 DENV se-
rotype or to Zika virus with minimal cross-neutralizing anti-
bodies were defined as primary flavivirus infections (mean-
ing that the 50% inhibitory concentration [IC50] for a single 
DENV serotype or Zika virus was >4-fold higher than for 
any other virus tested). In most cases, the person’s travel his-
tory corroborated the primary immune status. Serum that had 
high levels of neutralizing antibody to >2 flaviviruses were 
defined as secondary (repeat) flavivirus infections. Most sec-
ondary infection samples were from persons who had resid-
ed in DENV- or Zika virus–endemic countries for >5 years.
Viruses and Cells
Zika Virus Stocks
The MR766 and Dakar 41519 strains of Zika virus were 
obtained from R. Tesh (World Reference Center for 
Emerging Viruses and Arboviruses, University of Texas 
Medical Branch, Galveston, TX, USA) (20,21). The Cen-
ters for Disease Control and Prevention (Atlanta, GA, 
USA) provided Zika virus strains H/PF/2013 and PRV-
ABC59 (22,23).
DENV Stocks
All in vitro assays were conducted with the DENV World 
Health Organization reference strains: DENV-1 West Pac 
74, DENV-2 S-16803, DENV-3 CH54389, and DENV-4 
TVP-360 (initially obtained from R. Putnak, Walter Reed 
Army Institute of Research, Silver Spring, MD, USA). Virus 
stocks were prepared in C6/36 Aedes albopictus mosquito 
cells (ATCC no. CRL-1660) or Vero Cercopithecus aethiops 
monkey cells (ATCC no. CCL-81). C6/36 cells were grown 
at 32°C with 5% CO2 in minimum essential medium supple-
mented with 10% fetal bovine serum (FBS), L-glutamine, 
nonessential amino acids, and HEPES (2-hydroxyethyl)-
1-piperazineethanesulfonic acid) buffer. Vero cells were 
grown at 37°C with 5% CO2 in Dulbecco modified Eagle 
medium supplemented with 5% FBS and L-glutamine. Vi-
rus stocks were titrated on Vero cells by plaque assay or 
focus-forming assay (24). Infected cell foci were detected 
at 40–48 h after infection, after fixation with 1%–2% para-
formaldehyde and incubation with 500 ng/mL of flavivirus 
cross-reactive mouse monoclonal antibody (mAb) E60 (25), 
2H2 (26), and/or 4G2 (26). After incubation with a 1:2,000 
dilution of horseradish peroxidase–conjugated goat anti-
mouse IgG (Sigma, St. Louis, MO, USA), foci were detect-
ed by addition of TrueBlue substrate (KPL). We analyzed 
foci with a CTL Immunospot instrument (CTL, Cleveland, 
OH, USA). All studies were conducted under biosafety level 
 2 containment.
ELISA
We measured binding of human serum IgG to DENV or 
Zika virus by ELISA as previously described (27). In brief, 
DENV virions were captured by the anti-E protein mouse 
mAb 4G2, blocked with 3% normal goat serum (GIBCO 
Life Technologies, Carlsbad, CA, USA) or 3% nonfat dairy 
milk (LabScientific, Inc., Highlands, NJ, USA), and incu-
bated with human serum at indicated dilutions at 37°C for 
1 h, and binding was detected with an alkaline phospha-
tase–conjugated antihuman secondary antibody (Sigma) and 
p-nitrophenyl phosphate substrate (Sigma). Absorbance at 
405 nm was measured on an Epoch plate reader (BioTek, 
Suwanee, GA, USA). ELISAs used to confirm depletion 
were performed as given earlier, with the exception that 50 
ng purified DENV was coated directly to the plate at 37°C 
for 1 h at 1:50 dilution before serum was tested. ELISA data 
are reported as optical density values that are the average of 
technical replicates, unless otherwise indicated. The average 
optical density for technical replicates using naive human se-
rum at the same dilution factor as test samples serves as the 
negative control in ELISAs. In depletion experiments, the 
OD of depleted sample is expressed as percentage of control 
from same serum for some graphs as indicated.
Neutralization Assays
We adapted the previously described focus-reduction neu-
tralization test (FRNT) (28) to a 96-well format (18). Neu-
tralization titers were determined by FRNT by serial 3-fold 
dilution of human serum and mixing with ≈50–100 focus-
forming units of virus in Dulbecco modified Eagle medium 
with 2% FBS. The virus–antibody mixtures were incubated 
for 1 h at 37°C and then transferred to a monolayer of Vero 
cells for titration by focus assay as described earlier. For 
neutralization assays, we calculated IC50 values by using 
the sigmoidal dose response (variable slope) equation of 
Prism 6 (GraphPad Software, San Diego, CA, USA). One 
set of DENV-1–4 neutralization values (DT003) was deter-
mined previously by U937 flow-based assay (29), but Zika 
virus neutralization was determined by Vero FRNT. IC50 
values shown for certain Zika virus-immune serum sam-
ples were determined on 24-well plaque assay (30) (Table 
1). Reported values were required to have an R2 >0.75, a 
hill slope >0.5, and an IC50 within the range of the assay.
Depletions
As previously described (31), purified viral antigen for de-
pletions was obtained by infecting Vero cell cultures in 850 
cm2 roller bottles (Greiner Bio-One, Monroe, NC, USA) 
with DENV and then concentrating DENV-containing su-
pernatants at 4°C by tangential flow ultrafiltration using the 
Pellicon mini system with a 100-kD cutoff membrane (Pel-
licon-2 mini Holder and Pellicon-2 Mini Filters; Millipore, 
Darmstadt, Germany). The flow rate was 400 mL/min, and 
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filtration rate was ≈100 mL/min; pressure was 20–30 psi. 
Concentrated virus was then purified on a 15%–65% sucrose 
gradient by ultracentrifugation (SW 40 Ti, Beckman Coul-
ter, Brea, CA, USA) at 21,583 relative centrifugal force for 
18 h at 4°C. The fractions with maximal content of virus 
was determined by resolving fractions by SDS-PAGE and 
protein concentration was measured by Micro BCA Protein 
Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA).
Purified viral antigen was conjugated to Polybeads 
polystyrene 4.5-µ microspheres (PolyScience, Niles, IL, 
USA) in accordance with the manufacturer’s instructions 
(100 µg/250 µL beads) by incubating overnight at room tem-
perature. Control beads were incubated with equal amount of 
bovine serum albumin. Beads were blocked with 10 mg/mL 
bovine serum albumin, washed 3 times with 0.1 M borate 
buffer (pH 8.5), followed by 3 times with phosphate buffered 
saline. For depletion, serum was diluted 1:10 in phosphate 
buffered saline and incubated with 100 µg DENV-1 + 100 
µg DENV-2 divided over 3 rounds at 37°C for 1 h each. 
After incubation, tubes were centrifuged at 20,800 relative 
centrifugal force to pellet beads with bound antibodies, and 
serum was pipetted off the undisturbed pellet and transferred 
to new vials. We confirmed depletion efficacy with direct 
binding ELISA. Serum with higher titers of binding antibod-
ies was subjected to additional rounds of depletion until IgG 
binding was reduced to background levels.




Table 1. DENV or Zika virus neutralization profiles for persons with travel history to Zika virus–endemic areas* 
Serostatus, serum sample ID Place of Infection 
IC50† 
DENV-1 DENV-2 DENV-3 DENV-4 Zika virus 
Primary DENV-1       
 147 Latin America 3,552 287 557 75 <20 
 153 Latin America 757 <20 <20 <20 <20 
 05/262 Asia 274 <20 <20 <20 <20 
 06/125 Asia 3,823 222 125 80 <20 
 99/1230 Asia 1,219 63 30 24 <20 
Primary DENV-2       
 001 Asia 49 2,188 48 89 <20 
 08/90 Asia <20 2,966 <20 <20 <20 
 08/91 Asia <20 838 <20 <20 <20 
 09/165 Asia <20 2,093 <20 <20 <20 
 09/251 Asia <20 417 <20 <20 <20 
Primary DENV-3       
 116 Asia 200 979 5,342 290 <20 
 118 Latin America 173 374 3,041 56 <20 
 125 Latin America 99 97 1,648 35 <20 
 133 Latin America 89 171 3,348 83 <20 
 06/297 Asia 27 <20 573 <20 <20 
Primary DENV-4       
 112 Latin America 908 1367 591 18,408 <20 
 06/105 Asia <20 <20 <20 941 <20 
 06/302 Asia <20 <20 <20 4,130 <20 
 09/159 Asia 115 226 478 5,694 <20 
Primary Zika virus       
 168 Latin America 36ǂ <20 78‡ <20 1,382 
 172 Latin America <20 <20 <20 <20 8,468 
Secondary DENV       
 000 Asia 3,306 2,087 1,162 782 <20 
 003 Asia 556 178 299 <20 146 
 115 Asia 100 355 830 245 <20 
 141 Latin America 1,902 1,953 4,530 664 <20 
 144 Asia 155 191 5,782 1,612 699 
 145 Asia 601 1,262 240 60 <20 
 146 Asia 403 1,052 1,480 451 28 
 155 Asia 215 299 71 27 <20 
 160 Latin America 947 3,564 131 1,600 <20 
 06/123 Asia 1,776 827 82 157 <20 
 06/124 Asia 1,454 1,208 1,673 1,011 <20 
 09/157 Asia 282 1,104 73 134 <20 
 09/250 Asia 375 1475 151 94 <20 
Secondary Zika virus       
 165 Latin America 60‡ 79‡ 70‡ 508 1655 
 166 Latin America 929 393 4344 240 1814 
*DENV, dengue virus; IC50, 50% inhibitory concentration; ID, identification. 
†All neutralization testing performed on Vero cells with the exception of DT003, which was limiting and historic values performed on a U937 Flow-based 
assay are shown for DENV-1–4. Zika virus IC50 values for DT003 are from Vero assays. 
‡Curves that did not pass quality metrics are marked. Such curves might signify very low titer IC50 values or variable background at the lower limit of 




To study human antibody interactions between DENV 
and Zika virus, we assembled 36 late convalescent serum 
samples from persons exposed to DENV, Zika virus, or 
both (Table 1). The panel comprised serum from 21 per-
sons exposed to primary flavivirus infections (with each 
DENV serotype represented and 2 cases of Zika virus) and 
serum from 15 persons exposed to >2 flavivirus infections, 
including 2 persons exposed to both DENV and Zika virus.
We measured total IgG binding to DENV and Zika vi-
rus using a virus capture ELISA. We observed extensive 
cross-reactivity between DENV serotypes and between 
DENV and Zika virus, confirming that cross-reactive bind-
ing antibodies are maintained for many years after infec-
tion (Figure 1). Although cross-reactive binding antibod-
ies are commonly detected in flavivirus-immune serum, 
neutralization assays are more specific and can distinguish 
between previous exposure to various flaviviruses or even 
between different DENV serotypes (32). We therefore test-
ed whether convalescent serum antibodies in persons ex-
posed to DENV cross-neutralize Zika virus by a Vero cell–
based neutralization assay. Serum from persons exposed 
to primary DENV infection of any serotype did not cross-
neutralize Zika virus (Table 1; online Technical Appen-
dix Figure 1, https://wwwnc.cdc.gov/EID/article/23/5/16-
1630-Techapp1.pdf). In contrast, Zika virus was readily 
neutralized by serum from persons who had traveled to 
Brazil (DT168) and Colombia (DT172) in 2015 and expe-
rienced acute illnesses consistent with an arbovirus infec-
tion. Both serum samples strongly neutralized Zika virus, 
showing low or no cross-neutralization of the 4 DENV 
serotypes (Table 1; online Technical Appendix Figure 1, 
panels C, D), consistent with primary Zika virus infection.
Persons exposed to secondary DENV infections de-
velop broadly neutralizing antibodies that neutralize even 
DENV serotypes not encountered by that person (33). We 
determined the neutralization profile for 13 serum samples 
from persons with secondary DENV. Although the potency 
of neutralization varied, all but 1 (DT155) of the 13 samples 
had high levels of neutralizing activity (IC50 >100) against 
at least 3 DENV serotypes, and 7 were highly neutralizing 
against all 4 serotypes (Table 1). Despite this extensive 
cross-reactivity, most (10 [77%]) secondary DENV-immune 
serum samples failed to neutralize Zika virus (Table 1; on-
line Technical Appendix Figure 1). Serum from 1 person 
showed low levels of cross-neutralizing activity (DT146), 
and 2 serum samples (DT003 and DT144) had high levels 
of Zika virus neutralizing antibodies. Two donors (DT165 
and 166) reported suspected Zika virus infections acquired 
while in Brazil in 2015 during a known Zika virus outbreak. 
Serum from these 2 persons also neutralized Zika virus and 
>1 DENV serotypes, indicating that these most likely rep-
resent secondary Zika virus infections (online Technical 
Appendix, Figure 1, panels E, F). These results demonstrate 
that the broadly cross-neutralizing antibody response that is 
a hallmark of repeat DENV infections is mainly confined to 
the DENV serocomplex, although in some cases these anti-
bodies also might cross-neutralize Zika virus.
Zika virus strains are divided into 2 genotypes, Asian 
and African; contemporary Zika virus isolates from Latin 
America are uniformly of the Asian genotype, consistent 
with the model that Zika virus spread from Southeast Asia 
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Figure 1. Binding of DENV immune serum to Zika virus virions. Zika virus and 4 DENV serotypes were captured by using plate-bound 
mouse monoclonal antibody 4G2 and incubated with serum from donors who had had a primary DENV, secondary DENV, or primary Zika 
virus infection. In 2 separate experiments (A, B), serum binding was detected by using a horseradish peroxidase–conjugated human IgG. 
C, D) Differential global binding of each virus was accounted for by subtracting background from native human serum and normalizing to a 
high binding serum common to both plates (DT144). DENV, dengue virus; NHS, naive human serum; OD, optical density.
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to Oceania and from there to Brazil (34). To evaluate the 
effect of Zika virus strain variation on cross-neutralization, 
we tested selected DENV and Zika virus–immune serum 
against 4 Zika virus strains representing diverse temporal 
and geographic origins (Table 2). All 4 strains exhibited 
similar neutralization patterns, specifically that they were 
neutralized by serum from primary (DT168 and DT172) or 
secondary (DT165 and DT166) Zika virus cases, but not by 
serum from a secondary DENV infection (DT145) (Table 2; 
online Technical Appendix Figures 2, 3), supporting the idea 
that Zika virus exists as a single serotype. Zika virus strain 
MR766 was relatively more susceptible than other strains to 
neutralization, and it was the only strain to exhibit even low-
level neutralization by secondary DENV serum (IC50 67). In 
general, IC50 titers were similar for primary Zika virus serum 
and for secondary Zika virus serum, consistent with the idea 
that cross-reactive antibodies from prior DENV infection do 
not contribute to Zika virus neutralization.
To test the hypothesis that Zika virus infection elicits 
type-specific antibody, even in the presence of DENV im-
munity, we incubated serum with polystyrene beads coated 
with purified DENV antigen to remove DENV-specific and 
flavivirus cross-reactive antibody (Figure 2, Table 3). We 
then assessed binding and neutralization of Zika virus by 
the depleted serum. IgG binding to DENV-1 and DENV-2 
antigen was lower in depleted serum than in control serum, 
confirming success of this method (Figure 3, panel A). IgG 
binding to captured Zika virus was lower when DENV-
immune serum was depleted, but depletion only partially 
reduced binding from secondary Zika virus serum and had 
little effect on serum from primary Zika virus infections 
(Figure 3, panels B–E). Depletion successfully removed 
DENV neutralizing antibodies because depleted serum from 
primary DENV-2 (DT001), secondary DENV (DT000), and 
secondary Zika virus (DT165 and 166) cases all exhibited 
marked reductions in ability to neutralize DENV-2 (Figure 
4, Table 3). Also, broadly neutralizing serum lost the ability 
to neutralize a heterologous DENV serotype (DENV-4) af-
ter depletion, establishing that cross-neutralizing antibodies 
were effectively removed from these sera (Figure 4, Table 
3). Zika virus neutralization activity was entirely maintained 
after DENV depletion of serum from persons with primary 
Zika virus (DT168 and 172) and mostly preserved in deplet-
ed serum from persons with secondary Zika virus (DT165 
and 166), even when neutralization activity was lost to all 
DENV serotypes tested (Figure 4, Table 3). 
Discussion
Because Zika virus is emerging in areas with high rates of 
dengue prevalence, the extent of antibody cross-reactivity 




Table 2. Zika virus stains and neutralization in selected serum* 
Strain Genotype Origin Year Reference 
Serum sample ID, IC50 
DT168 DT172 DT165 DT166 
MR766 African Uganda 1947 (21) 2,546 2,898 1,918 3,890 
DAK41519 African Senegal 1982 (22) 700 1,186 547 1,203 
H/PF/2013 Asian Tahiti 2013 (23) 609 531 516 469 
PRVABC59 Asian Puerto Rico 2015 (24) 436 1,606 Not tested Not tested 





Table 3. 50% Inhibitory concentrations for serum in depletion 
experiments of DENV and Zika virus* 
Serum sample ID DENV-2 DENV-4 Zika virus 
DT000    
 Control 744 612 29 
 Depleted <20 <20 <20 
DT001    
 Control 1,376 60 <20 
 Depleted 331 24 <20 
DT168    
 Control 83 48 1,978 
 Depleted <20 <20 2,351 
DT172    
 Control 22 32 2,341 
 Depleted <20 <20 2,046 
DT165    
 Control 198 162 3,067 
 Depleted 31 78 2,060 
DT166    
 Control 1,556 1,138 1,090 
 Depleted <20 126 873 
*DENV, dengue virus; ID, identification. Specific antibodies were depleted 
using beads coated with DENV1 and DENV2 antigens. Beads coated with 
BSA were used as a control. 
 
Figure 2. Schematic of the method used for depletion of human 
serum with DENV antigen to distinguish Zika virus–specific from 
cross-reactive flavivirus antibodies. Serum was incubated with 
DENV-1 and DENV-2 coated on polystyrene beads, enabling 
removal of DENV-specific and cross-reactive antibodies. DENV, 
dengue virus.
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between these 2 viruses needs to be thoroughly evaluated. 
Recent studies have reported that DENV infection results 
in antibodies that cross-neutralize Zika virus (15,16,18). 
Plasmablasts isolated from patients during or immediately 
after recovery from acute DENV infection produced anti-
bodies that cross-neutralized Zika virus in cell culture (35) 
and were protective in a mouse model of Zika virus infec-
tion (18). Priyamvada et al. (16) demonstrated moderate to 
high-titer Zika virus neutralization in serum from 9 DENV-
infected persons; Zika virus neutralization activity was 
maintained out to 100 days of convalescence in 1 of the 5 
persons with paired samples. They further reported that 7 
of 47 mAbs derived from plasmablasts from 4 patients with 
acute DENV infection cross-neutralized Zika virus.
Our data do not demonstrate frequent and high-level 
cross-neutralization of Zika virus after exposure to DENV. 
Of 19 persons who had recovered from primary DENV in-
fections, none showed cross-neutralization of Zika virus. 
Among persons exposed to repeat DENV infections, 3 
(23%) of 13 showed Zika virus neutralizing antibodies. The 
remaining 10 persons had no detectable Zika virus neutral-
izing antibodies despite having high levels of neutralizing 
antibodies to multiple DENV serotypes. DT165 and 166 
are classified as secondary Zika virus strains on the basis 
of neutralization profile, epidemiologic context (these do-
nors had fever and rash illness while residing in northeast-
ern Brazil in 2015 during peak Zika virus transmission), 
and the presence of Zika virus type–specific antibodies in 
their serum. Accordingly, these persons have high titers of 
neutralizing antibodies to Zika virus in addition to neutral-
ization activity to >1 DENV serotypes. These results are 
consistent with those reported by Swanstrom et al., who 
found that only 1 of 16 persons exposed to repeat DENV 
infections had Zika virus IC50 values >1:100 (18). Low- 
level cross-neutralization to heterologous DENV serotypes 
is also observed into late convalescence after primary 
DENV infection; however, this phenomenon typically does 
not preclude accurate diagnosis of the originally infecting 
DENV serotype, nor does it confer immunity to secondary 
DENV infection by heterologous serotypes (30,36).
A key feature of acute DENV infection is the transient 
induction of high levels of flavivirus cross-neutralizing and 
cross-protective antibody (33). Over a few months, the neu-
tralizing antibody response becomes more specific to >1 
DENV serotypes, with little to no cross-neutralization of 
viruses belonging to other flavivirus serocomplexes (33). 
Timing of sample collection probably explains high levels 
of DENV–Zika virus cross-neutralizing antibodies observed 
by only some groups. Barba-Spaeth et al. (15) and Priyam-
vada et al. (16) performed their studies with blood samples 
collected from patients a few days to weeks after recovery 
from acute DENV infection, when overall antibody response 
is known to be broadly cross-neutralizing. In contrast, our 
studies were performed with samples collected >6 months 
after infection when the neutralizing antibody response has 
become more specific to the viruses responsible for infection.
In essence, the question is whether Zika virus will be-
have as a “fifth serotype” of DENV or as a flavivirus outside 
the DENV serocomplex. Extensive cross-reactivity in IgG 
binding between these viruses clearly occurs, consistent with 
sequence homology and structural similarity among different 
flavivirus serocomplexes (10,12). However, binding does not 
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Figure 3. Use of depletion of human serum with DENV antigen to distinguish Zika virus–specific from cross-reactive flavivirus 
antibodies. A) Depletion efficiency was determined by direct ELISA. Plates were coated with depleting antigens (DENV-1 and DENV-2) 
and binding of control and depleted serum was measured. B–E) Binding of depleted serum to Zika virus H/PF/2013 was measured by 
capture ELISA. BSA, bovine serum albumin; DENV, dengue virus; OD, optical density.
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reliably predict functional outcomes, such as neutralization, 
enhancement, or protection, and our results suggest that 
most persons infected with DENVs do not maintain high 
levels of Zika virus neutralizing antibodies 6 months after 
DENV infection. Although Zika virus is genetically more 
closely related to the DENVs than to other flaviviruses, the 
long-lived antibody cross-neutralization within the DENV 
serocomplex does not extend to Zika virus in most of our 
cohort. Furthermore, our data indicate that a population of 
Zika virus–specific neutralizing antibodies develops after 
Zika virus infection, even in the presence of preexisting 
DENV immunity. The corollary is that cross-reactive anti-
bodies and memory B cells from the prior DENV infection 
are not the major source of Zika virus neutralizing antibod-
ies; rather, de novo priming of naive B cells by Zika elicits 
Zika type-specific antibody responses. Thus, we propose 
that Zika virus does not belong to the DENV serocomplex 
and that DENV-immune persons will remain susceptible to 
Zika virus infection. Moreover, live attenuated tetravalent 
DENV vaccines are being evaluated for safety and efficacy 
in Asia and Latin America. Our results indicate that DENV 
neutralizing antibody induced by these vaccines are unlikely 
to protect against Zika virus infection.
In the field, undifferentiated fever in the tropics can 
have a multitude of causes and often presents a diagnostic 
challenge (37). Molecular detection of Zika virus has good 
specificity but is not ideal for diagnosing it in persons who 
seek care many days after illness onset or have asymptom-
atic infection. Simple serologic assays based on binding an-
tibody are difficult to interpret because of flavivirus cross-
reactivity (9,10). This scenario, typified by DT144, 165, and 
166, whereby flavivirus exposure history is uncertain with 
currently available assays (IgG or IgM ELISA), represents 
a critical challenge facing public health systems throughout 
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Figure 4. Lack of contribution of 
cross-reactive DENV antibodies 
to Zika virus neutralization. 
Immune serum was depleted 
with DENV-1 and DENV-2 
antigens bound to polystyrene 
beads, and neutralization activity 
was measured against DENV-2 
(A), DENV-4 (B), and Zika virus 
(C) for indicated serum. DENV, 
dengue virus. Dilutions are 1:the 
value given.
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the tropics where billions of persons are at risk for DENV 
and Zika virus infections (38). Our results suggest that the 
classical flavivirus plaque/focus reduction neutralization 
test might be reliable for determining previous Zika virus 
infection, particularly in the setting of retrospective serologic 
surveys and vaccine trials. We also note that the neutraliza-
tion test is not reliable for testing samples collected during 
or soon after recovery from a DENV or Zika virus infection 
because of temporarily broad cross-neutralization and poor 
specificity. Indeed, US public health laboratories and others 
have reported on the poor specificity of testing for Zika virus 
in acute or early convalescent samples using currently avail-
able tests and algorithms (39–42). On the basis of our studies 
using samples collected at late convalescence, we propose 
that the neutralization assay might retain utility for support-
ing Zika virus and DENV vaccine and other clinical trials; 
population-level serosurveillance; and clinical management 
of some patients, such as pregnant women, when blood sam-
ples are collected many months after a suspected infection.
Interest and investigation are ongoing regarding whether 
Zika virus strain–dependent factors might explain phenom-
ena observed during the current epidemic. Although a more 
comprehensive and in-depth analysis of Zika virus genetic 
variation might reveal viral determinants of pathogenesis, 
our experiments suggest that epitopes conferring suscepti-
bility to neutralization by human serum have not changed 
substantially over time. We do find that the prototype Zika 
virus strain MR766 is more readily neutralized than other 
Zika virus strains. MR766 might provide the most sensitive 
screen for cross-neutralizing antibody, but relevance of such 
antibody should be confirmed by an isolate more represen-
tative of contemporary circulating viruses.
In conclusion, the current Zika virus epidemic pres-
ents many urgent challenges but also great opportuni-
ties to dramatically expand our knowledge of humoral 
immunity to flaviviruses. Although our results argue for 
infrequent cross-neutralization of Zika virus by DENV-
immune serum and for development of independent 
populations of neutralizing antibody to these 2 viruses, 
additional and larger studies are needed to determine 
whether the rate of Zika virus cross-neutralization varies 
in different populations, particularly in DENV-endem-
ic areas where ongoing subclinical exposure to DENV 
could further broaden the range of cross-neutralization 
in polyclonal serum. That effective vaccines have been 
developed against several flaviviruses is encouraging 
(43–46), but much remains to be learned about Zika 
virus–specific antibody responses and the dynamics of 
cross-reactive antibody in persons with multiple flavi-
virus exposures. Knowledge on these fronts will better 
inform Zika virus vaccine development, rational design 
of serodiagnostic tests, and general understanding of an-
tibody responses to related viruses.
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